ProKidney Corp. (PROK) Stock Analysis

ProKidney Corp. (PROK) is a publicly traded company in the HEALTHCARE sector. It trades at $1.90, carries a market capitalization of $558.81M. This page summarizes the public market data, fundamentals, and frequently asked questions for PROK, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.90
• Market Cap: $558.81M
• EPS: $-0.53
• 52-Week High: $5.95
• 52-Week Low: $0.54

Market Sentiment

ProKidney Corp. currently has a Neutral sentiment score of 0.02.

About ProKidney Corp.

ProKidney Corp., based in Winston-Salem, North Carolina, is a leading biotechnology firm dedicated to revolutionizing the management of chronic kidney disease (CKD). The company's innovative approach focuses on cell-based therapies designed to restore kidney function and enhance the quality of life for patients suffering from this pervasive condition. With a strong development pipeline and a mission centered on advancing renal health, ProKidney is well-positioned in the biopharmaceutical land...

GNG Research Analysis

GNG Research scores ProKidney Corp. (PROK) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PROK.

Frequently Asked Questions

Does PROK pay dividends?

ProKidney Corp. (PROK) does not currently pay a regular dividend.

What is PROK's market cap?

ProKidney Corp. (PROK) has a market capitalization of $558.81M with a current stock price of $1.90.